Clinical Trial Update: Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone [Phase 4]

View source ↗

Summary

Phase 4 study evaluating ipragliflozin on excess fat in people with type 2 diabetes and non-alcoholic fatty liver disease who are on metformin and pioglitazone;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• ipragliflozin (ipragliflozin)

Snippet

Sponsor: Yonsei University | Conditions: Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD) | Phase 4 | Status: COMPLETED